Overview

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Status:
Completed

Trial end date:
2020-02-10

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutant and KRAS wild-type colorectal cancer (CRC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Forty Seven, Inc.
Gilead Sciences

Collaborator:

California Institute for Regenerative Medicine (CIRM)

Treatments:

Cetuximab
Magrolimab